Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15300231 | 0.73 | ACE2 (0.55) | ACE2KCNK9KCNK3CASP3KMT2A | |
| SCHEMBL20777907 | 0.72 | ACHE (0.58) | ACE2KCNK9KCNK3CASP3KMT2A | |
| SCHEMBL4289564 | 0.70 | ACE2 (0.97) | ACE2KCNK9KCNK3CASP3KMT2A | |
| SCHEMBL25970373 | 0.70 | ACE2 (0.97) | ACE2KCNK9KCNK3CASP3KMT2A | |
| SCHEMBL11527428 | 0.69 | ALDH1A1 (0.69) | ACE2CASP3KMT2APOLBMEN1 | |
| SCHEMBL8528763 | 0.68 | ACE2 (1.00) | ACE2KCNK9KCNK3CASP3KMT2A | |
| SCHEMBL30519331 | 0.68 | ACE2 (1.00) | ACE2KCNK9KCNK3CASP3KMT2A | |
| SCHEMBL2298254 | 0.68 | KCNK3 (1.00) | KCNK9KCNK3KMT2APOLBMEN1 | |
| SCHEMBL14715851 | 0.67 | KMT2A (0.79) | KCNK9KCNK3KMT2APOLBMEN1 | |
| SCHEMBL7990078 | 0.67 | RAB9A (0.54) | KCNK9KCNK3KMT2APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190070165-A1 | N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION | SAINT LOUIS UNIVERSITY (US) | 2019-03-07 | — | — | US | disclosed |
| WO-2017161133-A1 | N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION | SAINT LOUIS UNIVERSITY (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190070165-A1 | N-HYDROXYISOQUINOLINEDIONE INHIBITORS OF HBV REPLICATION | HCCS, HAVCR2, HDGF | ACE2 1397/4885KCNK9 4821/4885KCNK3 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.